Eisai-Therapeutic Portfolios-Therapeutic Portfolio | Cardiovasculars | Company & Drug | Global | 2024
- The document complements our standalone (detailed) company profile (which emphasis on clinical aspects more) by adding the business facet covering overall strategy, Geographical focus, Therapy area evolution within the portfolio, SWOT analysis- and how the company’s business has evolved in the last couple of years.
- The document gives a bird eyes view about the expected sales performance of the company covering the top-performing brands and therapy area focus based on their adopted business strategy. And how the company is fairing compared to its peers and what ranking changes are expected by the end of the forecast period.
Related Market Assessment Reports
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
